MSN receives tentative USFDA nod for generic version of Cangrelor
Hyderabad: Close on the heels of securing DCGI’s approval for Canreal injection (generic version of Cangrelor) in India, Hyderabad-based MSN Laboratories, received tentative approval for generic version of Cangrelor from the USFDA. Cangrelor is an intravenously administered antiplatelet drug that is used at the time of cardiac surgery or percutaneous coronary intervention to decrease the […]
Hyderabad: Close on the heels of securing DCGI’s approval for Canreal injection (generic version of Cangrelor) in India, Hyderabad-based MSN Laboratories, received tentative approval for generic version of Cangrelor from the USFDA.
Cangrelor is an intravenously administered antiplatelet drug that is used at the time of cardiac surgery or percutaneous coronary intervention to decrease the risk of myocardial infarction and maintain artery and stent patency.
MSN Group stated, “Besides reflecting the capability of MSN Laboratories to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.”
The drug will be manufactured at a FDA and MHRA approved state-of-the-art injectable facility in Hyderabad.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
